Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 华熙生物（688363.SH）成立于2000年，是全球知名的生物科技公司和生物材料公司。公司以合成生物科技为驱动，致力于不断提高生命质量、延长生命长度，为人类带来健康、美丽、快乐的生命体验。 秉承“让每个生命都是鲜活的”企业使命，华熙生物主要聚焦在功能糖、蛋白质、多肽、氨基酸、核苷酸、天然活性化合物等有助于生命健康的生物活性物开发和产业化应用。 作为生物科技全产业链平台型企业，公司业务目前涵盖生物活性物原料、医疗终端产品、消费终端产品（功能性护肤品和功能性食品）。公司坚信科技创新是发展的原动力，坚持人才是发展的基石和保障，以科学技术为底层根基，以制造和产业转化为树干，以市场转化为树冠，在实现自身发展的同时，赋能“万亿级”生命健康产业“森林”。 公司不但是全球最大的透明质酸研发、生产及销售企业，透明质酸产业化水平居世界首位。同时，利用合成生物技术，在gamma-氨基丁酸、5-氨基乙酰丙酸、依克多因、麦角硫因、人乳寡糖、硫酸软骨素、肝素、胶原蛋白、beta-烟酰胺单核苷酸（NMN）等生物活性物上逐步实现产业转化。 公司坚持“科学→技术→产品→品牌”的企业发展逻辑，坚持对基础研究和应用基础研究的不断投入，目前已建成合成生物学研发平台、微生物发酵平台、应用机理研发平台、中试转化平台、交联技术平台、配方工艺研发平台在内的六大研发平台，同外部科研院所积极展开合作，大力推动“产学研”一体化，加快科研成果的产业转化和市场转化。 一直以来，华熙生物坚信企业的生命力来源于持续不断的创新能力和持续不断的经营盈利能力。坚持“三链同构”，力争在产业链上成为行业标准的制定者和引领者，在供应链上成为控制中间环节的关键纽带，在价值链上成为资源优化配置的核心中枢。 未来，华熙生物将秉持“长期主义”发展观，依托科技力、打造产品力、塑造品牌力、从而获得竞争力、使企业真正具备免疫力。做出让中国人自信、自豪的国民产品，成为让世界尊敬、喜爱的民族企业。
Main Business 聚焦功能糖、蛋白质、多肽、氨基酸、核苷酸、天然活性化合物等六大类生物活性物的研发、生产和销售。
Legal Representative 赵燕
Top Executives
董事长：赵燕
董事：李亦争,郭珈均,郭学平,樊媛,邹松岩
独立董事：陈关亭,王颖千,曹富国
Top 5 Shareholder
Shareholder name Nature Holding Date
华熙昕宇投资有限公司限售股58.86%31/03/2024
国寿成达（上海）健康产业股权投资中心（有限合伙）流通A股7.15%31/03/2024
招商银行股份有限公司－华夏上证科创板50成份交易型开放式指数证券投资基金流通A股2.72%31/03/2024
香港中央结算有限公司流通A股1.45%31/03/2024
中国工商银行股份有限公司－易方达上证科创板50成份交易型开放式指数证券投资基金流通A股1.28%31/03/2024
Company Secretary 李亦争
Solicitors 北京市通商律师事务所
Auditors 致同会计师事务所（特殊普通合伙）
Tel No 010-85670603
Fax No 010-65630000
Website www.bloomagebiotech.com
Email ir@bloomagebiotech.com
Company Address
Register: 山东省济南市高新技术开发区天辰大街678号
Office: 山东省济南市高新技术开发区天辰大街678号；北京市朝阳区建国门外大街甲六号华熙国际中心D座33层
Listing Date 06/11/2019
Shares Capital
Shares Capital: 481,678,242
Total A Share: 481,678,242
Listed A Share: 198,178,242
Non-tradable A Share: 283,500,000
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.230
DPS(RMB)* ¥ 0.380
NBV Per Share(RMB)* ¥ 14.416
Market Capitalization(RMB) 12.563B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.